Nyxoah SA (NYXH) Stock Research Report

Nyxoah’s Genio is a leadless, battery-free, bilateral sleep-apnea implant with massive U.S. upside—but the stock is a high-beta bet on execution, funding, and a patent-court outcome.

Executive Summary

Nyxoah SA is an innovation-led medtech company focused on neuromodulation for obstructive sleep apnea, with a dual listing on Nasdaq and Euronext Brussels. Its core product, the Genio system, is a minimally invasive, leadless and battery-free hypoglossal nerve stimulation therapy designed for patients who do not achieve success with CPAP. The company sells the implant and external system components and benefits from a recurring consumables stream (nightly adhesive patches/activation elements), creating attractive lifetime value per patient once implanted. After FDA PMA in August 2025, the U.S. becomes the dominant opportunity, supported by strong reimbursement and an estimated ~$10B TAM. Genio’s main competitive advantages versus the incumbent Inspire include bilateral stimulation, a simpler single-incision surgical workflow, and elimination of future battery replacement surgeries. The investment case is therefore a classic adoption-curve story: if Nyxoah can scale center-of-excellence penetration, maintain rapid sequential revenue growth, and expand indications (notably CCC), it could become a meaningful category share winner. The bear case centers on legal, financing, and rollout bottlenecks rather than the underlying clinical rationale.

Full Research Report

Nyxoah SA (NYXH) Investment Analysis:

1. Executive Summary:

Nyxoah SA represents a transformative entrant in the medical technology sector, specifically targeting the global crisis of obstructive sleep apnea (OSA). Headquartered in Mont-Saint-Guibert, Belgium, and maintaining a dual listing on the Nasdaq and Euronext Brussels, the company is fundamentally an innovation-driven enterprise focused on neuromodulation.[1, 2] The core mission of the firm is centered on the commercialization of the Genio system, a leadless, battery-free, and minimally invasive hypoglossal nerve stimulation (HGNS) therapy designed for patients who have failed to achieve clinical success with Continuous Positive Airway Pressure (CPAP).[1, 3, 4]

The company generates revenue through the sale of its proprietary hardware and a recurring consumables model. The primary revenue driver is the Genio implant, a passive neurostimulator surgically placed via a single incision under the chin.[5, 6] Complementing this is the sale of external components, specifically the activation chips and disposable adhesive patches that patients must apply nightly to power and control the implant.[7, 8] This "razor-and-blade" economic structure ensures that the initial surgical intervention seeds a long-term revenue stream through consumables.[7, 8]

Nyxoah’s primary customer base consists of Ear, Nose, and Throat (ENT) surgeons and sleep physicians operating within specialized sleep centers and high-volume medical institutions.[5, 9] These professionals act as the primary gatekeepers for therapy adoption. The end markets are geographically diversified but increasingly concentrated in the United States, following the August 2025 FDA Premarket Approval (PMA).[3, 10, 11] The U.S. market represents the most significant opportunity due to its robust reimbursement environment and a total addressable market (TAM) estimated at $10 billion.[5, 11]

Customers, both clinicians and patients, choose Nyxoah over the entrenched incumbent, Inspire Medical Systems, due to several key differentiators. From a clinical perspective, the Genio system provides bilateral stimulation—activating both branches of the hypoglossal nerve to move the tongue forward symmetrically—which has demonstrated high efficacy in supine (back-sleeping) positions.[3, 5, 12] Surgically, the single-incision approach reduces operative time to roughly 45–60 minutes and avoids the complications associated with the chest-implanted pulse generators and sensing leads required by legacy systems.[5, 6, 13] For the patient, the lack of an internal battery eliminates the need for future revision surgeries for battery replacement, providing a "lifetime" solution that is fully upgradeable through external hardware and software updates.[3, 12, 14]

Disruptive Neuromodulation Challenger

2. Business Drivers & Strategic Overview:

Product and Service Detail

The technical architecture of the Genio system is the primary driver of Nyxoah’s strategic positioning. The system’s leadless design removes the most common failure points in traditional neurostimulation: the physical leads that connect a pulse generator to the target nerve.[4, 12] By utilizing Radio Frequency (RF) energy transfer from an external wearable patch to a passive internal stimulator, Nyxoah has shifted the complexity of the device from the inside of the patient’s body to the outside.[1, 4]

The surgical procedure is a critical component of the value proposition. Because the device is placed through a single midline incision under the chin, surgeons do not have to perform the chest dissection or the tunneling of leads required by the incumbent technology.[4, 6] This simplifies the training curve and reduces the resources required by the hospital for each case.[5, 13] The current "skin-to-skin" procedure time averages 60 minutes, which is significantly faster than the 90–150 minutes typical for multi-component systems.[5, 6]

Feature Genio System Specification Investor Relevance
Stimulation Mode Bilateral Hypoglossal Nerve Activation [3, 15] Symmetrical tongue movement; superior supine performance.[5]
Implant Design Leadless, Battery-free, Passive [4, 12] No future surgery for battery replacement; reduced mechanical failure.[3]
Surgical Profile Single 2-3 cm incision under the chin [12, 14] Lower infection risk; faster throughput for surgical centers.[6]
Connectivity Smartphone-linked external wearable [14] Real-time monitoring; software-driven therapy optimization.[3, 14]
MRI Compatibility 1.5T and 3T Full-body compatibility [3, 4] Broadens patient eligibility; avoids clinical contraindications.[16]

Moat Analysis

Nyxoah’s competitive moat is constructed through a combination of high switching costs, regulatory barriers, and specialized intellectual property.

  • Surgical Switching Costs: Once a patient is implanted with the Genio stimulator, the surgical site is "occupied." Given the invasive nature of the procedure and the permanent placement of the electrode on the hypoglossal nerve, it is highly unlikely that a patient would transition to a competitor’s device.[6, 13] This creates a high-fidelity recurring revenue stream from the disposable patches for the 12+ year life of the device.[5, 8]
  • Regulatory and Clinical Barriers: The 2025 FDA approval was supported by the DREAM pivotal study, which demonstrated a 63.5% AHI responder rate and 71.3% ODI responder rate.[3, 14] Replicating this data set requires years of clinical trials and multi-million dollar investments, effectively locking out smaller startups.[9, 17]
  • Intellectual Property (IP): The company’s patents cover the unique bilateral stimulation protocol and the specific architecture of the leadless stimulator.[16] While these patents are currently being challenged by Inspire Medical Systems in a high-stakes Delaware lawsuit, they remain a primary defensive barrier for the company’s core technology.[16, 18]
  • Indication Monopoly (CCC): A potential "moat within a moat" exists in the Complete Concentric Collapse (CCC) segment. Nyxoah’s ongoing ACCESS study targets this specific phenotype, which is currently a contraindication for Inspire.[17, 19, 20] If approved, Nyxoah would be the only provider capable of treating approximately 20-30% of the moderate-to-severe OSA population.[21, 22]

TAM / Market Opportunity Analysis

The market opportunity for HGNS is vast and largely untapped. Globally, approximately 425 million people suffer from moderate-to-severe OSA.[2] In the United States alone, the TAM is valued at $10 billion, reflecting the high prevalence of the condition and the increasing failure of patients to adhere to CPAP therapy.[5, 11]

Strategic adoption is centered on "centers of excellence." There are roughly 400 high-volume surgical sites in the U.S. that account for the vast majority of HGNS procedures.[5, 9] Nyxoah's commercial strategy is to penetrate these specific accounts, with 125 targeted immediately at launch.[5] By the end of 2025, the company had already activated 57 accounts and trained 145 surgeons, indicating a rapid capture of initial "early adopter" clinician mindshare.[7, 8, 23]

Competitive Landscape

The competitive environment is dominated by a duopoly between Nyxoah and Inspire Medical Systems.[16, 24, 25]

Inspire Medical Systems (INSP) has been the category leader since 2014, with over 50,000 implants worldwide.[6, 25, 26] Inspire’s system utilizes a unilateral (one-sided) stimulation approach and requires a chest-implanted battery.[4, 6] While Inspire has the advantage of a long-established track record and extensive insurance coverage, its technology is often viewed as "pacemaker-era" due to the leads and internal battery.[6, 12, 16]

Nyxoah is currently gaining ground as the "technological disruptor." Clinician interest is driven by the single-incision procedure and the flexibility of a battery-free implant.[5, 12] Management believes they can capture up to 15% of patients who currently refuse surgery specifically because they do not want a device implanted in their chest.[5] Furthermore, Nyxoah’s partnership with ResMed in Germany creates a defensive alliance with the world’s largest sleep company, ensuring a steady funnel of patients who are not responding to CPAP.[22, 27, 28]

Disruptive Bilateral Challenger

3. Financial Performance & Valuation:

Recent Historical Performance (2025)

The 2025 fiscal year served as the definitive "launch year" for Nyxoah in the U.S. market. The company reported full-year net revenue of €10.0 million, a 122% increase over 2024.[7, 8] This growth was heavily back-weighted, with Q4 2025 generating €5.6 million in net revenue—a 347% year-over-year surge that reflects the first full quarter of U.S. commercialization.[7, 29]

Financial Metric FY 2024 Actual FY 2025 Actual YoY Change
Gross Revenue €4.5M €11.0M +144% [7, 8]
Net Revenue €4.5M €10.0M +122% [7, 8]
Gross Margin 66.0% 63.0% -300 bps [7, 8]
Operating Loss €(58.8)M €(83.5)M +42% [7, 29]
R&D Expense €34.3M €42.8M +25% [7, 29]
SG&A Expense €28.5M €48.3M +69% [7, 29]
Year-End Cash €85.6M €48.0M -44% [7, 8]

The slight compression in gross margin from 66% to 63% is attributed to the initial operational ramp-up and inventory build-ahead of the U.S. launch.[8, 30] Operating losses widened significantly as the company built out its U.S. commercial organization, which now includes over 50 professionals targeting high-volume accounts.[7, 9]

Financial Drivers and Valuation Context

Valuation for a company at Nyxoah’s stage is less about current earnings (which are deeply negative) and more about the "velocity of adoption" and the path to breakeven.

  1. Sales Velocity (Sequential Growth): Management has guided for approximately 25% sequential U.S. net revenue growth in both Q1 and Q2 2026.[7, 8, 31] This trajectory is critical for maintaining investor confidence.
  2. Rep Productivity: In Q4 2025, U.S. sales representatives demonstrated an annualized productivity of approximately $720,000 per rep.[11] As this metric matures toward the $1.5M - $2.0M range typical of established medtech reps, operating leverage will begin to manifest.
  3. Manufacturing Scale: Gross margins are expected to step up to ~70% in 2027 following the launch of the Genio 2.2 system and the optimization of the new 2,000 m² Belgian manufacturing facility.[11, 23, 32]
  4. Reimbursement Framework: Starting January 1, 2026, the CMS reimbursement for CPT 64568 (the code for Genio implants) will increase to approximately $45,000 for hospital outpatient departments, a 48% rise.[10, 33] This significantly improves the economic attractiveness of the procedure for surgical centers and supports higher average selling prices (ASPs).

Current Valuation Multiples

Nyxoah currently trades at an Enterprise Value to Sales (EV/Sales) multiple that is a significant discount to its peer group. With a market cap of ~$124 million and trailing revenue of €10M, the P/S is roughly 12x.[34, 35] While this may seem high for general equities, high-growth medtech pure-plays often trade at 8-20x revenue.[36] The "discount" in Nyxoah’s case likely accounts for the 16.7% share dilution over the past year and the persistent cash burn of ~€20 million per quarter.[11, 37, 38]

Rapid Commercial Scaling

4. Risk Assessment & Macroeconomic Considerations:

Company-Specific Execution Risks

The primary risk to the Nyxoah thesis is the "onboarding bottleneck." While surgeon interest is high, each new account must pass through a hospital’s Value Analysis Committee (VAC). This process can take up to nine months, and while Nyxoah has secured over 70 VAC approvals by the end of 2025, any slowdown in this institutional adoption would cripple sequential growth.[5, 9, 11] Furthermore, the company is still in the "unproven at scale" phase of its commercial rollout, where logistics and supply chain management become as important as the clinical technology itself.[11, 39]

Competitive and Legal Risks

The most significant headwind is the ongoing patent litigation in the U.S. District Court for the District of Delaware.[16, 18] Inspire Medical Systems is seeking an injunction that could, in the worst case, bar Nyxoah from the U.S. market.[16] While a settlement is considered 60-70% likely by legal analysts, a protracted battle or an unfavorable ruling could force Nyxoah into a high-royalty licensing agreement that erodes margins.[16] A jury trial is currently scheduled for December 2027.[18]

Customer Concentration and Reimbursement Risk

Nyxoah’s strategy of targeting the top 400 accounts means that a loss of a few key hospital systems would have a disproportionate impact on revenue.[5, 9] Additionally, while CMS has granted a massive reimbursement increase for 2026, any future reversal of these rates—similar to the recent CMS correction that affected Inspire—could damage the economic foundation of the therapy.[10, 40]

Balance Sheet and Capital Allocation Risks

With €48 million in cash and a quarterly burn rate approaching €20 million, Nyxoah has a runway only into Q1 2027.[7, 11] This necessitates another significant capital raise within the next 12-18 months. The company’s Altman Z-Score of -4.11 to -5.15 places it in the "distress zone," indicating that its survival is contingent on its ability to access capital markets or reach revenue-driven cash flow sustainability quickly.[38, 41]

Macroeconomic Sensitivities

As a provider of high-cost implantable devices, Nyxoah is sensitive to hospital capital expenditure cycles and broad economic conditions that might lead patients to defer elective surgeries. Furthermore, since the company operates in Euros but is ramping up expenses and revenue in U.S. Dollars, it faces significant foreign exchange (FX) risk.[42]

Risk Category What Could Go Wrong Early Warning Sign Long-Term Thesis Damage
Legal Permanent injunction in Delaware.[16] Denial of summary judgment motions. Total U.S. market exclusion.
Clinical ACCESS study misses endpoints.[17] Negative data leaks or trial suspensions. Loss of the CCC market segment.
Financial Failure to raise capital in late 2026.[11] Share price falling below $2.00. Terminal insolvency/Liquidation.
Execution VAC rejection rates exceed 20%.[5] Flat sequential revenue growth. Failure to achieve market parity with INSP.

High-Beta Binary Outcome

5. 5-Year Scenario Analysis:

Financial Projections and Assumptions (2026-2030)

The following projections are based on consensus revenue growth of 214% in 2026 and 124% in 2027, tapering toward a mature growth rate by 2030.[43]

Base Case: Successful Penetration and CCC Approval

The base case assumes Nyxoah maintains its guided 25% sequential growth through 2026 and successfully launches the Genio 2.2 in 2027. The ACCESS study leads to a CCC label expansion in early 2027, allowing Nyxoah to own a unique market segment.

  • Year 5 Revenue: €385 million.[43]
  • Operating Margin: 15.8% (achieving first-time EBIT profitability in 2029).[43]
  • Valuation Multiple: 6.0x EV/Revenue (reflecting a mature but high-growth medtech profile).
  • Share Count: 58 million (assuming two additional equity raises of $50M each at current prices).
  • Implied Share Price: ~$43.00.

High Case: Market Dominance and M&A Exit

The high case assumes the "bilateral advantage" becomes the preferred clinical choice. A favorable settlement with Inspire removes legal overhang, and ResMed exercises its "soft" interest to acquire the company to protect its sleep dominance.[26, 37]

  • Year 5 Revenue: €550 million.
  • Operating Margin: 25.0% (significant operating leverage on SG&A).
  • Valuation Multiple: 10.0x EV/Revenue (M&A premium).
  • Share Count: 52 million (minimal dilution due to high share price during raises).
  • Implied Share Price: ~$110.00.

Low Case: Legal Defeat and Stalled Growth

The low case assumes a loss in the patent trial, a 15% royalty burden, and a failure of the ACCESS study. The company remains a niche player with limited U.S. adoption.

  • Year 5 Revenue: €120 million.
  • Operating Margin: -5.0% (struggling to reach scale).
  • Valuation Multiple: 3.0x EV/Revenue (distressed asset valuation).
  • Share Count: 70 million (heavy dilution to maintain operations).
  • Implied Share Price: ~$5.50.

Scenario Summary Table

Scenario Year 5 Rev (Key Metric) Margin / Earnings Valuation Multiple Implied Share Price 5-Year Total Return Probability
High Case €550M 25.0% Op Margin 10.0x EV/Rev $110.00 ~3,700% 15%
Base Case €385M 15.8% Op Margin 6.0x EV/Rev $43.00 ~1,400% 55%
Low Case €120M -5.0% Op Margin 3.0x EV/Rev $5.50 ~90% 30%

Expected Probability Weighted Price Target: $41.80

Asymmetric Upside Potential

6. Qualitative Scorecard:

  • Management Alignment (8/10): Co-Founder Robert Taub maintains a ~10% stake in the company, and management recently participated in the €77M financing round alongside institutional investors.[44, 45] Compensation is high but generally aligned with the aggressive milestone-based nature of the company.[46, 47]
  • Revenue Quality (7/10): Improving significantly. The shift from one-off clinical trial implants to a full commercial "implants + consumables" model in the U.S. increases the predictability of cash flows.[7, 8]
  • Market Position (6/10): Challenger status. While Nyxoah is "winning" on technological innovation (bilateral stimulation, single incision), it is still "losing" on sheer market share to Inspire.[5, 24]
  • Growth Outlook (9/10): Exceptional. The combination of a $10B TAM, 25% guided sequential growth, and a unique upcoming indication for CCC creates a top-tier growth profile.[5, 11, 23]
  • Financial Health (3/10): Poor. High burn rate, Altman Z-score in the distress zone, and limited cash runway necessitate near-term capital market dependency.[38, 41]
  • Business Viability (6/10): Durable technology with a long device life (12+ years), but the Inspire patent lawsuit is a major potential "choke point".[16, 18]
  • Capital Allocation (5/10): Management is focused entirely on the high-growth U.S. opportunity, which is the correct strategic move, but the track record of shareholder dilution is a concern.[37, 46]
  • Analyst Sentiment (9/10): Overwhelmingly bullish. Analyst consensus targets (~$10-$11) imply 250% upside from current levels.[35, 43]
  • Profitability (1/10): No history of profits; significant losses expected to continue through 2028.[43, 48]
  • Track Record (7/10): Management has a strong history of meeting regulatory milestones (FDA approval, CE expansion) but has yet to translate that into sustained shareholder value.[46]

Overall Blended Score: 6.1 / 10

Speculative Execution Play

7. Conclusion & Investment Thesis:

Nyxoah SA sits at the center of a "David vs. Goliath" narrative in the sleep apnea market. The investment thesis for the company rests on three pillars: technological disruption, market under-penetration, and regulatory scarcity.[5, 11, 12] By offering a bilateral, leadless, and battery-free alternative to the status quo, Nyxoah is effectively addressing the primary pain points of both surgeons and patients.[5, 6]

The primary catalyst for the company is the continued 25% sequential U.S. revenue growth guided for 2026, which would validate the commercial viability of the Genio system.[7, 8] Secondary catalysts include the ACCESS study results in mid-2026 and a potential settlement of the Inspire litigation.[16, 17, 23] However, the thesis remains vulnerable to the company’s precarious financial position and the binary outcome of the Delaware patent trial.[16, 38]

For an investor, Nyxoah represents a high-conviction bet on the "future of neuromodulation." If the company can navigate its upcoming capital needs and secure its legal standing, it is well-positioned to capture a meaningful portion of a multi-billion dollar market.

High-Conviction Binary Bet

8. Technical Analysis, Price Action & Short-Term Outlook:

NYXH is currently in a confirmed technical downtrend. The stock is trading at ~$2.86, significantly below its 200-day moving average of ~$5.80 and near its 52-week low of $2.76.[32, 49, 50] Momentum indicators are negative, and the stock has underperformed the broader healthcare indices significantly over the past six months.[34, 50] Short-term outlook remains bearish until a clear reversal is signaled by high-volume buying following the Q1 2026 earnings release.

Bearish Technical Momentum

  1. NYXH Stock: Understanding Nyxoah S.A.'s Growth and Market Performance - Bitget, https://www.bitget.com/wiki/nyxh-stock
  2. | Nyxoah, https://nyxoah.com/
  3. FDA Grants Approval of Hypoglossal Nerve Stimulation System for Obstructive Sleep Apnea Treatment | NeurologyLive, https://www.neurologylive.com/view/fda-grants-approval-hypoglossal-nerve-stimulation-system-obstructive-sleep-apnea-treatment
  4. Inspire® vs. Genio™: Choosing the Right Hypoglossal Nerve Stimulator for Your Sleep Apnea - North Fulton ENT, https://northfultonent.com/inspire-vs-genio-for-sleep-apnea/
  5. Nyxoah Details Early U.S. Genio Launch, Reimbursement Update at ..., https://www.marketbeat.com/instant-alerts/nyxoah-details-early-us-genio-launch-reimbursement-update-at-oppenheimer-medtech-conference-2026-2026-03-21/
  6. Inspire vs Genio: Which Sleep Apnea Treatment Is Right for You? | Frisco TX, https://www.dreamsleepmedicine.com/services/inspire-vs-genio
  7. Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results, https://www.globenewswire.com/news-release/2026/03/19/3259442/0/en/Nyxoah-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-and-Operating-Results.html
  8. Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results, https://nyxoah.gcs-web.com/news-releases/news-release-details/nyxoah-reports-fourth-quarter-and-full-year-2025-financial-and/
  9. Nyxoah (NYXH) Q2 2025 Earnings Call Transcript | The Motley Fool, https://www.fool.com/earnings/call-transcripts/2025/08/18/nyxoah-nyxh-q2-2025-earnings-call-transcript/
  10. Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule - BioSpace, https://www.biospace.com/press-releases/nyxoahs-genio-therapy-receives-significant-2026-medicare-reimbursement-increases-under-final-cms-rule
  11. Nyxoah S.A. Stock Price: Quote, Forecast, Splits & News (NYXH) - Perplexity, https://www.perplexity.ai/finance/NYXH/earnings
  12. Sleep Apnoea Implants: Inspire & Nyxoah Genio - Vik Veer, https://consultant-surgeon.co.uk/osaimplants.html
  13. Nyxoah Genio for Sleep Apnea - Jordan Weiner, MD, https://weinersleepsurgery.com/treatments/genio-by-nyxoah/
  14. Nyxoah receives FDA approval for Genio system - American Academy of Sleep Medicine, https://aasm.org/nyxoah-receives-fda-approval-for-genio-system/
  15. Study Details | NCT05592002 | Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA. | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT05592002
  16. Inspire Vs. Nyxoah: The Patent Battle Behind Competition - iiprd, https://www.iiprd.com/inspire-vs-nyxoah-the-patent-battle-behind-competition/
  17. Cantor Fitzgerald reiterates Nyxoah stock rating on US launch - Investing.com, https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-nyxoah-stock-rating-on-us-launch-93CH-4575249
  18. 1:25-cv-00667 | Inspire Medical Systems, Inc. v. Nyxoah, Inc. et al | RPX Insight, https://litigation.rpxcorp.com/litigation/dedce-89290-inspire-medical-systems-v-nyxoah
  19. Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026, https://www.globenewswire.com/news-release/2026/03/05/3250651/0/en/Nyxoah-to-Release-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-March-19-2026.html
  20. Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026, https://www.biospace.com/press-releases/nyxoah-to-release-fourth-quarter-and-full-year-2025-financial-results-on-march-19-2026
  21. Earnings call: Nyxoah achieves robust sales growth, eyes FDA approval - Investing.com, https://www.investing.com/news/stock-market-news/earnings-call-nyxoah-achieves-robust-sales-growth-eyes-fda-approval-93CH-3327467
  22. Nyxoah Announces Partnership with ResMed in Germany, https://nyxoah.gcs-web.com/news-releases/news-release-details/nyxoah-announces-partnership-resmed-germany/
  23. Nyxoah (NYXH) Investor Relations, Earnings Summary & Outlook - Quartr, https://quartr.com/companies/nyxoah-s-a_16413
  24. Inspire Medical Systems Vs Nyxoah: Which is a Better Buy? AI Stock Analysis - Danelfin, https://danelfin.com/stocks/INSP-inspire-medical-systems-vs-NYXH-nyxoah-compare
  25. Sleep apnea market attracts new BioElectRx competitors - Neurotech Reports, https://www.neurotechreports.com/pages/sleep-apnea-market.html
  26. Competitive Evolution in the Sleep Apnea Market: Data, Diversification, and Digital Integration | Signify Research, https://www.signifyresearch.net/insights/competitive-evolution-in-the-sleep-apnea-market-data-diversification-and-digital-integration/
  27. Sleep Apnea Implants Market Report 2026, https://www.researchandmarkets.com/reports/6231910/sleep-apnea-implants-market-report
  28. Nyxoah Announces Partnership with ResMed in Germany | GlobeNewswire by notified - NTB Kommunikasjon, https://kommunikasjon.ntb.no/pressemelding/18003572/nyxoah-announces-partnership-with-resmed-in-germany?publisherId=4954260
  29. Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results, https://markets.businessinsider.com/news/stocks/nyxoah-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results-1035947817
  30. Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results, https://nyxoah.gcs-web.com/node/8031/pdf
  31. Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 - Euronext Markets, https://live.euronext.com/en/products/equities/company-news/2026-01-12-nyxoah-announces-preliminary-results-fourth-quarter-and
  32. Nyxoah at Oppenheimer Healthcare MedTech Conference | NYXH Stock News, https://www.stocktitan.net/news/NYXH/nyxoah-to-participate-in-the-oppenheimer-36th-annual-healthcare-med-orhctuli8p8b.html
  33. Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule - Hospitals Management, https://www.hospitals-management.com/news/nyxoahs-genio-therapy-receives-significant-2026-medicare-reimbursement-increases-under-final-cms-rule
  34. Nyxoah SA Share Price, Forecast & Financials (EBR:NYXH) | Stockopedia, https://www.stockopedia.com/share-prices/nyxoah-sa-EBR:NYXH/
  35. NYXH Stock Forecast 2026 - Nyxoah Price Targets & Predictions - Ticker Nerd, https://tickernerd.com/stock/nyxh-forecast/
  36. MedTech Valuation Multiples and Comparable Analysis | Healthcare IB Guide, https://ibinterviewquestions.com/guides/healthcare-investment-banking/medtech-valuation-multiples-comps
  37. Nyxoah SA Insider Trading & Ownership Structure - Simply Wall St, https://simplywall.st/stocks/us/healthcare/nasdaq-nyxh/nyxoah/ownership
  38. NYXH Forecasts Strong U.S. Revenue Growth in Early 2026, https://www.gurufocus.com/news/8727772/nyxh-forecasts-strong-us-revenue-growth-in-early-2026
  39. Nyxoah S.A. Stock Price: Quote, Forecast, Splits & News (NYXH) - Perplexity, https://www.perplexity.ai/finance/NYXH
  40. CMS removes OSA coverage for Inspire Medical Systems reimbursement uplift, https://www.investing.com/news/analyst-ratings/cms-removes-osa-coverage-for-inspire-medical-systems-reimbursement-uplift-93CH-4461176
  41. Nyxoah (NYXH) Sees Strong Revenue Growth Following US Commercial Launch, https://www.gurufocus.com/news/4106991/nyxoah-nyxh-sees-strong-revenue-growth-following-us-commercial-launch
  42. Form 6-K/A for Nyxoah SA filed 11/17/2025, https://nyxoah.gcs-web.com/static-files/e8c1fe17-309d-43d3-836a-61a418768438
  43. NYXH.BR Forecast, Price Target & Analyst Ratings | NYXOAH SA ..., https://www.chartmill.com/stock/quote/NYXH.BR/analyst-ratings
  44. Nyxoah says Robert Taub holds 10.14% voting rights | NYXH Stock News, https://www.stocktitan.net/news/NYXH/publication-relating-to-transparency-gewe9ks3773m.html
  45. Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio - BioSpace, https://www.biospace.com/press-releases/nyxoah-secures-financing-commitments-of-up-to-u-s-77-million-to-drive-u-s-commercialization-of-genio
  46. Nyxoah SA (NYXH) Leadership & Management Team Analysis ..., https://simplywall.st/stocks/us/healthcare/nasdaq-nyxh/nyxoah/management
  47. Nyxoah SA (NYXH) Leadership & Management Team Analysis - Simply Wall St, https://simplywall.st/stocks/be/healthcare/ebr-nyxh/nyxoah-shares/management
  48. Nyxoah Reports Q4 Loss and Revenue Miss Despite 348% Year-Over-Year Revenue Growth - MLQ.ai, https://mlq.ai/news/nyxoah-reports-q4-loss-and-revenue-miss-despite-348-year-over-year-revenue-growth/
  49. Nyxoah (NYXH) Stock price today - quote & chart - Kraken, https://www.kraken.com/stocks/nyxh
  50. Buy Nyxoah Stock - NYXH Stock Price, Quote & News | SoFi, https://www.sofi.com/invest/stock/NYXH/

View Nyxoah SA (NYXH) stock page

Loading the interactive version of this report…